KOR

e-Article

Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real‐world efficacy from the EoE CONNECT registry
Document Type
Report
Source
United European Gastroenterology Journal. June, 2024, Vol. 12 Issue 5, p585, 11 p.
Subject
Pharmacists -- Comparative analysis
Medical research -- Comparative analysis
Medicine, Experimental -- Comparative analysis
Corticosteroids -- Comparative analysis
Deglutition disorders -- Care and treatment
Esophagitis -- Care and treatment
Fluticasone -- Comparative analysis
Prescription writing -- Comparative analysis
Evidence-based medicine -- Comparative analysis
Language
English
Abstract
Background: Swallowed topical corticosteroids (tC) are common therapy for patients with eosinophilic esophagitis (EoE). Widely heterogeneous results have occurred due to their active ingredients, formulations and doses. Objective: To assess the effectiveness of topical corticosteroid therapy for EoE in real‐world practice. Methods: Cross‐sectional study analysis of the multicentre EoE CONNECT registry. Clinical remission was defined as a decrease of ≥50% in dysphagia symptom scores; histological remission was defined as a peak eosinophil count below 15 per high‐power field. The effectiveness in achieving clinico‐histological remission (CHR) was compared for the main tC formulations. Results: Overall, data on 1456 prescriptions of tC in monotherapy used in 866 individual patients were assessed. Of those, 904 prescriptions with data on formulation were employed for the induction of remission; 234 reduced a previously effective dose for maintenance. Fluticasone propionate formulations dominated the first‐line treatment, while budesonide was more common in later therapies. A swallowed nasal drop suspension was the most common formulation of fluticasone propionate. Doses ≥0.8 mg/day provided a 65% CHR rate and were superior to lower doses. Oral viscous solution prepared by a pharmacist was the most common prescription of budesonide; 4 mg/day provided no benefit over 2 mg/day (CHR rated being 72% and 80%, respectively). A multivariate analysis revealed budesonide orodispersible tablets as the most effective therapy (OR 18.9, p < 0.001); use of higher doses (OR 4.3, p = 0.03) and lower symptom scores (OR 0.9, p = 0.01) were also determinants of effectiveness. Conclusion: Reduced symptom severity, use of high doses, and use of budesonide orodispersible tablets particularly were all independent predictors of tC effectiveness.
Key summary Established knowledge * Topical corticosteroids (tC) are widely used to induce and maintain EoE remission in real practice. However, different products provide very heterogeneous results due to the [...]